Lite Strategy Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Jay File

İcra Kurulu Başkanı

US$912.7k

Toplam tazminat

CEO maaş yüzdesi	59.35%
CEO görev süresi	2.8yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	3.9yrs
Yönetim Kurulu ortalama görev süresi	1.9yrs

Son yönetim güncellemeleri

Recent updates

Analiz Makalesi • Feb 17

New Forecasts: Here's What Analysts Think The Future Holds For MEI Pharma, Inc. (NASDAQ:MEIP)

MEI Pharma, Inc. ( NASDAQ:MEIP ) shareholders will have a reason to smile today, with the analysts making substantial...

Analiz Makalesi • Dec 30

Increases to CEO Compensation Might Be Put On Hold For Now at MEI Pharma, Inc. (NASDAQ:MEIP)

Key Insights MEI Pharma to hold its Annual General Meeting on 05 January 2023 CEO Dan Gold's total compensation...

Analiz Makalesi • Nov 19

Need To Know: Analysts Are Much More Bullish On MEI Pharma, Inc. (NASDAQ:MEIP)

Celebrations may be in order for MEI Pharma, Inc. ( NASDAQ:MEIP ) shareholders, with the analysts delivering a...

Analiz Makalesi • May 18

We're Hopeful That MEI Pharma (NASDAQ:MEIP) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Analiz Makalesi • Mar 26

Need To Know: The Consensus Just Cut Its MEI Pharma, Inc. (NASDAQ:MEIP) Estimates For 2022

The analysts covering MEI Pharma, Inc. ( NASDAQ:MEIP ) delivered a dose of negativity to shareholders today, by making...

Analiz Makalesi • Feb 12

Newsflash: MEI Pharma, Inc. (NASDAQ:MEIP) Analysts Have Been Trimming Their Revenue Forecasts

Market forces rained on the parade of MEI Pharma, Inc. ( NASDAQ:MEIP ) shareholders today, when the analysts downgraded...

Seeking Alpha • Feb 01

MEI Pharma: Another PI3K Delta Progressing To The FDA

MEIP's lead asset is zandelisib, an oral PI3K delta inhibitor. In two studies in Follicular lymphoma, zandelisib has shown strong data. What should concern MEI is the FDA's issue with safety for the entire PI3K delta class.

Analiz Makalesi • Dec 02

Need To Know: Analysts Just Made A Substantial Cut To Their MEI Pharma, Inc. (NASDAQ:MEIP) Estimates

One thing we could say about the analysts on MEI Pharma, Inc. ( NASDAQ:MEIP ) - they aren't optimistic, having just...

Analiz Makalesi • Nov 04

We're Not Very Worried About MEI Pharma's (NASDAQ:MEIP) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analiz Makalesi • Feb 25

The Independent Non-Executive Director of MEI Pharma, Inc. (NASDAQ:MEIP), Frederick Driscoll, Just Sold 40% Of Their Holding

We'd be surprised if MEI Pharma, Inc. ( NASDAQ:MEIP ) shareholders haven't noticed that the Independent Non-Executive...

Analiz Makalesi • Feb 11

New Forecasts: Here's What Analysts Think The Future Holds For MEI Pharma, Inc. (NASDAQ:MEIP)

Celebrations may be in order for MEI Pharma, Inc. ( NASDAQ:MEIP ) shareholders, with the analysts delivering a...

CEO Tazminat Analizi

Jay File'un ücretlendirmesi Lite Strategy'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Mar 31 2026	n/a	n/a	-US$61m
Dec 31 2025	n/a	n/a	-US$40m
Sep 30 2025	n/a	n/a	-US$12m
Jun 30 2025	US$913k	US$542k	-US$16m
Mar 31 2025	n/a	n/a	-US$32m
Dec 31 2024	n/a	n/a	-US$38m
Sep 30 2024	n/a	n/a	-US$47m
Jun 30 2024	US$615k	US$450k	US$18m
Mar 31 2024	n/a	n/a	US$26m
Dec 31 2023	n/a	n/a	US$20m
Sep 30 2023	n/a	n/a	US$41m
Jun 30 2023	US$321k	US$26k	-US$32m

Tazminat ve Piyasa: Jay 'nin toplam tazminatı ($USD 912.67K ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 629.02K ).

Tazminat ve Kazançlar: Jay şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Jay File (55 yo)

2.8yrs

Görev süresi

US$912,667

Tazminat

Mr. Justin J. File, also known as Jay, serves as CFO & Corporate Secretary at Lite Strategy, Inc. (formerly known as MEI Pharma, Inc.) since August 01, 2023 and served as its Acting Chief Executive Officer...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Justin File	CEO, CFO	2.8yrs	US$912.67k	Veri yok
Anne Frese	Chief People Officer	3.9yrs	Veri yok	Veri yok
Robert Mass	Strategic Advisor	14.9yrs	US$755.98k	Veri yok

3.9yrs

Ortalama Görev Süresi

Deneyimli Yönetim: LITS 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.9 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Justin File	CEO, CFO	less than a year	US$912.67k	Veri yok
Frederick Driscoll	Independent Chairperson	8.3yrs	US$98.53k	0.0052% $ 2.2k
Nicholas Glover	Independent Non-Executive Director	12.9yrs	US$70.60k	0% $ 0
Charles Lee	Non-Executive Director	1.3yrs	Veri yok	0.80% $ 342.1k
James Flynn	Independent Director	2.5yrs	US$60.30k	0.28% $ 117.0k
Joshua Riezman	Non-Executive Director	less than a year	Veri yok	0% $ 0

1.9yrs

Ortalama Görev Süresi

50.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: LITS 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 1.9 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/05/16 21:16
Gün Sonu Hisse Fiyatı	2026/05/15 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2025/06/30

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Lite Strategy, Inc. 10 Bu analistlerden 0, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Stephen V. Byrne	BofA Global Research
Leah Rush Cann	Brookline Capital Markets
Daniel Brims	Cantor Fitzgerald & Co.

Lite Strategy Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Insider recently sold US$946k worth of stock

MEI Pharma, Inc. Announces Board Changes

MEI Pharma, Inc., Annual General Meeting, Jan 30, 2025

MEI Pharma, Inc. Announces Management Changes

MEI Pharma, Inc., Annual General Meeting, Dec 18, 2023

MEI Pharma, Inc. Announces Board Changes

Recent updates

New minor risk - Insider selling

Insider recently sold US$946k worth of stock

New major risk - Financial position

Lite Strategy, Inc. (NasdaqCM:LITS) announces an Equity Buyback for $25 million worth of its shares.

New minor risk - Market cap size

New major risk - Share price stability

New major risk - Shareholder dilution

MEI Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

MEI Pharma, Inc. announced that it has received $99.999401 million in funding from GSR, Litecoin Foundation Ltd., Mozayyx Management LLC, RLH Capital, LLC, Delta Blockchain Fund LP, CoinFund LLC

MEI Pharma, Inc. Announces Board Changes

New minor risk - Share price stability

MEI Pharma, Inc., Annual General Meeting, Jan 30, 2025

MEI Pharma, Inc. Announces Management Changes

MEI Pharma, Inc. Announces Strategic Plan to Leverage Recent Positive Voruciclib and ME-344 Clinical Data

MEI Pharma, Inc. Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients

MEI Pharma, Inc. Reports Update from Clinical Study Evaluating Oral Cdk9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia

MEI Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $10.3 million.

MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib At ASH2023

MEI Pharma, Inc., Annual General Meeting, Dec 18, 2023

MEI Pharma, Inc. Declares Special Cash Dividend of Common Stock, Payable on December 6, 2023

MEI Pharma Announces Acceptance of Abstract for Presentation at ASH 2023

MEI Pharma, Inc. Announces Board Changes

MEI Pharma, Inc. to Report Fiscal Year 2023 Results on Sep 26, 2023

MEI Pharma, Inc. Announces First Patient Dosed in Clinical Study Evaluating ME-344 Plus Bevacizumab (AVASTIN) in Patients with Previously Treated Metastatic Colorectal Cancer

MEI Pharma, Inc. Announces Chief Financial Officer Changes, Effective as of August 1, 2023

MEI Pharma, Inc. Announces Change of CFO, Effective No Later Than September 1, 2023

MEI Pharma, Inc. Announces Executive Changes

Funicular Fund, LP, managed by Cable Car Capital, LLC, Anson Funds Management LP, Anson Advisors Inc., Anson Management GP LLC, Bruce R. Winson, Amin Nathoo and Moez Kassam submitted a proposal to acquire remaining 85.2% stake in MEI Pharma, Inc. (NasdaqCM:MEIP) for $45.4 million.

MEI Pharma, Inc Announces Update of Ongoing Phase 1 Study Evaluating Oral CDK9 Inhibitor Voruciclib Alone and in Combination with Venetoclax in Patients with Acute Myeloid Leukemia or B-Cell Malignancies

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New Forecasts: Here's What Analysts Think The Future Holds For MEI Pharma, Inc. (NASDAQ:MEIP)

Consensus revenue estimates increase by 61%

Price target decreased by 12% to US$2.27

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Insufficient new directors

Increases to CEO Compensation Might Be Put On Hold For Now at MEI Pharma, Inc. (NASDAQ:MEIP)

Price target decreased to US$2.90

Consensus revenue estimates increase by 26%

Need To Know: Analysts Are Much More Bullish On MEI Pharma, Inc. (NASDAQ:MEIP)

Price target increased to US$5.83

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

MEI Pharma, Inc., Annual General Meeting, Dec 06, 2022

Consensus forecasts updated

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$4.81

We're Hopeful That MEI Pharma (NASDAQ:MEIP) Will Use Its Cash Wisely

Consensus revenue estimates increase by 11%

Consensus revenue estimates increase by 11%

Need To Know: The Consensus Just Cut Its MEI Pharma, Inc. (NASDAQ:MEIP) Estimates For 2022

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Newsflash: MEI Pharma, Inc. (NASDAQ:MEIP) Analysts Have Been Trimming Their Revenue Forecasts

No longer forecast to breakeven

MEI Pharma: Another PI3K Delta Progressing To The FDA

Need To Know: Analysts Just Made A Substantial Cut To Their MEI Pharma, Inc. (NASDAQ:MEIP) Estimates

Consensus revenue estimates fall to US$38.1m

Price target increased to US$10.89

Independent Non Executive Director Kevan Clemens has left the company

First quarter 2022 earnings released: US$0.10 loss per share (vs US$0.019 loss in 1Q 2021)

We're Not Very Worried About MEI Pharma's (NASDAQ:MEIP) Cash Burn Rate

Price target increased to US$11.11

Full year 2021 earnings released: US$0.45 loss per share (vs US$0.51 loss in FY 2020)

Forecast to breakeven in 2024

Consensus revenue estimates fall to US$18.3m

Third quarter 2021 earnings released: US$0.28 loss per share (vs US$0.041 loss in 3Q 2020)

Independent Non-Executive Director notifies of intention to sell stock

The Independent Non-Executive Director of MEI Pharma, Inc. (NASDAQ:MEIP), Frederick Driscoll, Just Sold 40% Of Their Holding

Independent Non-Executive Director recently sold US$101k worth of stock

New Forecasts: Here's What Analysts Think The Future Holds For MEI Pharma, Inc. (NASDAQ:MEIP)

Analysts update estimates